Millennium Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Millennium Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-976,384	Closed	-$1.16M	–	7481
2022 Q3	$1.16M	Sell	976,384 -4,423,940	-82%	-$6.9M	﹤0.01%	4204
2022 Q2	$9.72M	Buy	5,400,324 +1,798,313	+50%	+$2.65M	0.01%	2070
2022 Q1	$7.28M	Buy	3,602,011 +2,525,471	+235%	+$4.96M	﹤0.01%	2519
2021 Q4	$2.92M	Buy	1,076,540 +492,367	+84%	+$1.82M	﹤0.01%	3409
2021 Q3	$2.6M	Sell	584,173 -1,720,201	-75%	-$8.29M	﹤0.01%	3601
2021 Q2	$13.4M	Buy	2,304,374 +79,770	+4%	+$467K	0.01%	1566
2021 Q1	$15.6M	Buy	2,224,604 +1,335,581	+150%	+$8.95M	0.01%	1321
2020 Q4	$4.27M	Buy	889,023 +767,531	+632%	+$3.88M	﹤0.01%	2591
2020 Q3	$708	Sell	121,492 -108,427	-47%	-$649K	﹤0.01%	3372
2020 Q2	$1.55M	Buy	+229,919	New	+$1.74M	﹤0.01%	2712
2019 Q4	–	Sell	-395,237	Closed	-$1.55M	–	4762
2019 Q3	$1.55M	Buy	395,237 +124,527	+46%	+$1.01M	﹤0.01%	2607
2019 Q2	$4.03M	Buy	270,710 +224,586	+487%	+$4.06M	0.01%	1942
2019 Q1	$1.15M	Buy	46,124 +17,015	+58%	+$427K	﹤0.01%	2782
2018 Q4	$523K	Buy	29,109 +20,988	+258%	+$429K	﹤0.01%	2940
2018 Q3	$239K	Buy	+8,121	New	+$314K	﹤0.01%	3576
2018 Q2	–	Sell	-248,377	Closed	-$13.1M	–	4309
2018 Q1	$13.1M	Sell	248,377 -11,215	-4%	-$654K	0.02%	1157
2017 Q4	$17.7M	Buy	+259,592	New	+$18.1M	0.02%	982
2017 Q3	–	Sell	-147,217	Closed	-$13.8M	–	3988
2017 Q2	$13.8M	Sell	147,217 -386,769	-72%	-$23.7M	0.02%	873
2017 Q1	$34M	Sell	533,986 -541,548	-50%	-$32.9M	0.06%	445
2016 Q4	$47.8M	Buy	1,075,534 +411,510	+62%	+$14.5M	0.1%	282
2016 Q3	$23.9M	Buy	664,024 +366,925	+124%	+$7.87M	0.04%	501
2016 Q2	$4.08M	Buy	297,099 +6,688	+2%	+$97.8K	0.01%	1377
2016 Q1	$5.58M	Sell	290,411 -883,462	-75%	-$18.7M	0.01%	1187
2015 Q4	$41.1M	Buy	1,173,873 +876,068	+294%	+$56.5M	0.09%	297
2015 Q3	$27.4M	Buy	+297,805	New	+$25.8M	0.05%	434
2015 Q2	–	Sell	-47,800	Closed	-$3.55M	–	3985
2015 Q1	$3.55M	Sell	47,800 -855	-2%	-$60.4K	0.01%	1614
2014 Q4	$2.73M	Sell	48,655 -124,972	-72%	-$6.57M	0.01%	1766
2014 Q3	$7.88M	Buy	173,627 +110,402	+175%	+$4.61M	0.02%	1002
2014 Q2	$2.62M	Sell	63,225 -183,783	-74%	-$9.47M	0.01%	1596
2014 Q1	$17.1M	Buy	247,008 +46,873	+23%	+$3.44M	0.05%	520
2013 Q4	$12.1M	Buy	200,135 +145,065	+263%	+$7.89M	0.04%	592
2013 Q3	$3.35M	Sell	55,070 -330,309	-86%	-$23.4M	0.01%	1353
2013 Q2	$25.8M	Buy	+385,379	New	+$17.3M	0.08%	222

Other funds holding CLVS

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management's CLVS Position: Q4 2022 in Review

Millennium Management sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 976,384 shares — an estimated $1.16M sold.

Millennium Management first reported a position in CLVS in Q2 2013 and held it in 33 quarters. The position peaked at $47.8M in Q4 2016. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

Millennium Management reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
Millennium Management sold 976,384 Clovis Oncology, Inc. shares in Q4 2022, an estimated $1.16M.
Millennium Management first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 33 quarters.
Millennium Management's Clovis Oncology, Inc. position peaked at $47.8M in Q4 2016.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.